Skip to main content
. 2019 Apr 6;17(4):215. doi: 10.3390/md17040215

Figure 7.

Figure 7

Schema of phomaketide A-induced anti-lymphangiogenic mechanism in human LECs. This study reveals phomaketide A as a promising anti-lymphangiogenic agent. Phomaketide A may inhibit lymphangiogenesis by decreasing VEGFR-3 and its downstream PKCδ and eNOS signaling pathways, as well as increasing protease inhibitors in human LECs.